7 terminated. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
Follow Spasm: new trials by email Literature Review of Spasm trials Research Report on Spasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) Guanfacine Hydrochloride Immediate Release, Placebo - Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome | Phase 2 | Terminated | Rachel G. Greenberg, MD, MB, MHS | 3 | 2024-12-09 | 2026-04-17 |
| Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD Cannabis oil - ADHD, Hyperactivity | Phase 2 | Terminated | Brlev Agricultural Crops Ltd | 8 | 2022-07-31 | 2023-04-25 |
| A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS) Radiprodil - Infantile Spasms (IS) | Phase 2 | Terminated | UCB Biopharma S.P.R.L. | 3 | 2017-12-04 | 2019-09-17 |
| A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps. FLX-787-ODT (orally disintegrating tablet), Placebo ODT - Charcot-Marie-Tooth Disease | Phase 2 | Terminated | Flex Pharma, Inc. | 27 | 2017-10-16 | 2018-08-29 |
| A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps. FLX-787-ODT (orally disintegrating tablet), Placebo ODT - Motor Neuron Disease | Phase 2 | Terminated | Flex Pharma, Inc. | 54 | 2017-07-28 | 2018-08-29 |
| Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection Calcium Aluminosilicate Anti-Diarrheal (CASAD) - Diarrhoea, Clostridium Difficile | Phase 2 | Terminated | Salient Pharmaceuticals Incorporated | 2 | 2012-03-01 | 2013-03-08 |
| Pilot Study Examining Effect for Dextroamphetamine to Treat Cocaine Dependence Plus Attention-deficit Hyperactivity Disorder (ADHD) Placebo, Dextroamphetamine SR - Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 5 | 2007-08-01 | 2012-02-22 |
Attention Deficit Disorder with Hyperactivity (2) · Muscle Cramp (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2) · Amyotrophic Lateral Sclerosis (1) · Charcot-Marie-Tooth Disease (1) · Cocaine-Related Disorders (1) · Diarrhea (1) · Epilepsy (1) · Hereditary Sensory and Motor Neuropathy (1) · Impulsive Behavior (1) · Infections (1) · Motor Neuron Disease (1)
Neurologic Manifestations (7) · Neuromuscular Manifestations (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Nervous System Diseases (5) · Attention Deficit and Disruptive Behavior Disorders (2) · Central Nervous System Diseases (2) · Mental Disorders (2) · Muscular Diseases (2) · Musculoskeletal Diseases (2) · Neurodevelopmental Disorders (2) · Behavior (1) · Brain Diseases (1) · Chemically-Induced Disorders (1) · Congenital Abnormalities (1)
Amphetamine (1) · Calcium Aluminosilicate (1) · Guanfacine (1) · nabiximols (1) · radiprodil (1)
Flex Pharma, Inc. (2) · Brlev Agricultural Crops Ltd (1) · Rachel G. Greenberg, MD, MB, MHS (1) · Salient Pharmaceuticals Incorporated (1) · The University of Texas Health Science Center, Houston (1) · UCB Biopharma S.P.R.L. (1)
United States (5) · France (1) · Israel (1)
Aarthi Narasimhan, MD (1) · Bjorn Oskarsson, MD (1) · David V Herin, Ph.D (1) · Mati Berkovitch (1) · Nicolas Johnson, MD (1) · Rachel Greenberg (1)
2016 (1), P50DA009262 (1)